STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
· On 18 April 2016, Recipharm announced that the Company had signed two separate agreements to acquire Kemwell’s pharmaceutical CDMO businesses. The EGM resolved pursuant to the proposal by the Board of Directors to authorize the Board of Directors, during the period until the next Annual General Meeting (the “AGM”), to issue new series B shares against payment in kind in the form of all shares in Kemwell AB.
· On 18 April 2016, Recipharm announced that the Company had signed two separate agreements to acquire Kemwell’s pharmaceutical CDMO businesses. The EGM resolved pursuant to the proposal by the Board of Directors to authorize the Board of Directors, during the period until the next Annual General Meeting (the “AGM”), to issue new series B shares against payment in kind in the form of all shares in Kemwell AB.
